Ranbaxy launches generic Lipitor in Denmark

“The introduction of atorvastatin in Denmark is a significant milestone in Ranbaxy's atorvastatin strategy and heralds the beginning of the company's determined efforts to bring affordable atorvastatin to patients in Europe and other parts of the world,” commented Malvinder Mohan Singh, CEO & managing director, Ranbaxy.

Lipitor is a cholesterol lowering medicine which is designed to reduce the risk of heart attack and stroke in patients.

The company said it will continue to actively pursue all options in the EU and other markets in order to bring affordable atorvastatin to patients around the world. Denmark is the first Western country to get the product.

Ranbaxy and Pfizer are still engaged in a lawsuit regarding validity of generic Lipitor in Denmark. The litigation concerns three Lipitor patents and if Ranbaxy loses it could be subject to financial penalties as compensation for Pfizer losing out on drug sales.